Personalized RNA-medicine for pancreatic cancer.

CONCLUSIONS:  This general approach appears suitable for co-clinical validation of personalized RNA medicine and paves the way to prospectively identify patients with eligible miRNA profiles for personalized RNA-based therapy.
PMID: 29330203 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 12, 2018 Category: Cancer & Oncology Authors: Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ Tags: Clin Cancer Res Source Type: research